Previously, we reported that bevacizumab, the anti‐human VEGFA monoclonal antibody (anti‐hVEGFA), delayed the onset of acquired resistance to BRAFi in a human melanoma tumor model developed in immunodeficient mice. Here, VEGFA is linked to neoplasm.